Science Explorer Back to mapMap
Discussion
Institution · EsSALUD

Most cited papers from EsSALUD

EsSALUD

What are the most cited papers from EsSALUD?

The most cited paper from EsSALUD is "Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men" (Robert M. Grant et al., 2010), with 5,186 citations. Next come "WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update" (1,106) and "Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men" (1,057).

Showing 50 of 60 papers. Every paper with more than 87 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men Robert M. Grant et al. · New England Journal of Medicine Open access 23 Nov 2010 5,186
2 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Dennis Falzon et al. · European Respiratory Journal Open access 2 Aug 2011 1,106
3 Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men Peter L. Anderson, David V. Glidden, Albert Liu et al. · Science Translational Medicine Open access 12 Sep 2012 1,057
4 Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis Neel R. Gandhi, Paul P. Nunn, Keertan Dheda et al. · The Lancet May 2010 1,035
5 The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis Keertan Dheda et al. · The Lancet Respiratory Medicine 23 Mar 2017 706
6 Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy Halle C. F. Moore et al. · New England Journal of Medicine Open access 4 Mar 2015 552
7 Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru Carole Diane Mitnick, Jaime Bayona, Eda Palacios et al. · New England Journal of Medicine Open access 8 Jan 2003 496
8 Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets Justin Micah Balko et al. · Cancer Discovery Open access 19 Dec 2013 486
9 Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis Carole Diane Mitnick et al. · New England Journal of Medicine Open access 6 Aug 2008 403
10 Programmes and principles in treatment of multidrug-resistant tuberculosis Joia S. Mukherjee, Michael Rich, Adrienne R. Socci et al. · The Lancet Feb 2004 335
11 Effect of water and sanitation on childhood health in a poor Peruvian peri-urban community William Checkley, Robert H. Gilman, Robert E. Black et al. · The Lancet 2004 298
12 Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance Justin Micah Balko, Rebecca S. Cook, David Vaught et al. · Nature Medicine Open access 10 Jun 2012 265
13 Single-cell eQTL models reveal dynamic T cell state dependence of disease loci Aparna Nathan, Samira Asgari, Kazuyoshi Ishigaki et al. · Nature Open access 11 May 2022 245
14 Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae Nicolas A. Menzies, Matthew Quaife, Brian W Allwood et al. · The Lancet Global Health Open access 16 Nov 2021 238
15 Using adult mosquitoes to transfer insecticides to Aedes aegypti larval habitats Gregor J. Devine, Elvira Zamora Perea, Gerry F. Killeen et al. · Proceedings of the National Academy of Sciences Open access 26 Jun 2009 221
16 GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions Maha Reda Farhat, Luca Freschi, Roger I. Calderon et al. · Nature Communications Open access 13 May 2019 206
17 Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study Cosette Marie Wheeler et al. · The Lancet Infectious Diseases 29 Jun 2016 194
18 SARS – CoV ‐2 Infection and COVID ‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis Richard P. Conway et al. · Arthritis & Rheumatology ReviewOpen access 22 Nov 2021 187
19 Multidrug-resistant Tuberculosis Management in Resource-limited Settings Eva Nathanson, Catharina Lambregts–van Weezenbeek, Michael Rich et al. · Emerging infectious diseases Open access Sep 2006 184
20 RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response Adam Penn‐Nicholson et al. · Scientific Reports Open access269 authors 25 May 2020 177
21 Burden of non-communicable diseases from infectious causes in 2017: a modelling study Matthew M Coates, Alexander Kintu, Neil Gupta et al. · The Lancet Global Health Open access 21 Oct 2020 172
22 Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? Joseph A. Pinto, Carlos Santiago Vallejos, Luis Estuardo Raez et al. · ESMO Open Open access 2018 171
23 Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies Ekaterina V. Kurbatova et al. · The Lancet Respiratory Medicine Open access 25 Feb 2015 164
24 Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial Marius M. Solomon et al. · Clinical Infectious Diseases Open access 13 Jun 2014 161
25 Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study Aditya Sharma et al. · The Lancet Infectious Diseases Open access 9 May 2017 155
26 HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial Susan Buchbinder, David V. Glidden, Albert Liu et al. · The Lancet Infectious Diseases Open access 8 Mar 2014 154
27 DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer Indira Tirado-Hurtado, Williams Fajardo, Joseph A. Pinto · Frontiers in Oncology Open access 12 Apr 2018 153
28 Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis J. Peter Cegielski et al. · Clinical Infectious Diseases Open access 23 Jul 2014 150
29 Risk Factors and Mortality Associated with Default from Multidrug‐Resistant Tuberculosis Treatment Molly Forrest Franke, Sasha C. Appleton, Jaime Bayona et al. · Clinical Infectious Diseases Open access 7 May 2008 146
30 Geographic variations in the PARADIGM-HF heart failure trial Søren Lund Kristensen et al. · European Heart Journal Open access 28 Jun 2016 141
31 Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis Omowunmi Aibana et al. · PLoS Medicine ReviewOpen access 11 Sep 2019 137
32 Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence Justin Micah Balko et al. · Science Translational Medicine Open access 13 Apr 2016 136
33 Peruvian Mental Health Reform: A Framework for Scaling-up Mental Health Services Mauricio Toyama, Humberto López Castillo, Jerome T. Galea et al. · International Journal of Health Policy and Management Open access 22 Jan 2017 125
34 Case Report: Pneumothorax and Pneumomediastinum as Uncommon Complications of COVID-19 Pneumonia—Literature Review Alvaro Quincho-Lopez, Dania L. Quincho-Lopez, Fernando D. Hurtado-Medina · American Journal of Tropical Medicine and Hygiene Open access 24 Jul 2020 123
35 Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study Susan Rachel Skinner et al. · International Journal of Cancer Open access 19 Dec 2015 120
36 Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial Ruth Pettengell, Bertrand Coiffier, Geetha Narayanan et al. · The Lancet Oncology 29 May 2012 120
37 Multimodally profiling memory T cells from a tuberculosis cohort identifies cell state associations with demographics, environment and disease Aparna Nathan, Jessica I. Beynor, Yuriy Baglaenko et al. · Nature Immunology Open access 24 May 2021 119
38 Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience Sonya S. Shin, Jennifer Joan Furin, Jaime Bayona et al. · Social Science & Medicine 28 Mar 2004 117
39 Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial Gustavo E. Velásquez, Meredith B. Brooks, Julia M. Coit et al. · American Journal of Respiratory and Critical Care Medicine Open access 29 Jun 2018 115
40 Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer Jhajaira M. Araujo, Andrea C. Gómez, Alfredo Aguilar et al. · Scientific Reports Open access 14 Mar 2018 111
41 Cultural adaptation of birthing services in rural Ayacucho, Peru Sabine Gabrysch, Claudia Patricia Henao Lema, Eduardo Bedriñana et al. · Bulletin of the World Health Organization Open access Sep 2009 108
42 Expanding mental health services in low- and middle-income countries: A task-shifting framework for delivery of comprehensive, collaborative, and community-based care Paul A. Bolton et al. · Cambridge Prisms Global Mental Health Open access 2023 105
43 Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance J. Peter Cegielski et al. · Clinical Infectious Diseases Open access 27 Oct 2015 103
44 The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study Gabriela B. Gomez, Annick Bórquez, Carlos F. Cáceres et al. · PLoS Medicine Open access 9 Oct 2012 98
45 Impact of Vitamin A and Carotenoids on the Risk of Tuberculosis Progression Omowunmi Aibana, Molly Forrest Franke, Chuan-Chin Huang et al. · Clinical Infectious Diseases Open access 18 May 2017 96
46 A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure John J.V. McMurray et al. · European Heart Journal Open access 21 Nov 2014 96
47 Independent Population Validation of the Belin/Ambrósio Enhanced Ectasia Display: Implications for Keratoconus Studies and Screening Ovette F. Villavicencio, Fatimah Gilani, Maria Alejandra Henriquez et al. · International Journal of Keratoconus and Ectatic Corneal Diseases Open access 2014 95
48 Validation and Abbreviation of an HIV Stigma Scale in an Adult Spanish-Speaking Population in Urban Peru Molly Forrest Franke, Maribel Muñoz, Karen E. Finnegan et al. · AIDS and Behavior Open access 7 Oct 2008 95
49 Drivers of stunting reduction in Peru: a country case study Luis Huicho, Elisa Vidal-Cárdenas, Nadia Akseer et al. · American Journal of Clinical Nutrition Open access 4 Jun 2020 93
50 Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension Athanasios J. Manolis, Ehud Grossman, Bojan Jelaković et al. · Clinical Therapeutics Oct 2000 93

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.